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ABSTRACT 
Background:  Brain-derived  neurotrophic  factor  (BDNF)  is  the  most  widely  expressed 
member  of  the  neurotrophin  family  in  the  human  brain  and  is  crucially  involved  in  the 
development of neural circuits, modulation of synaptic plasticity, and regulation of cognitive 
functions,  including  learning  and  memory.  Many  studies  have  shown  the  association  of 
altered  BDNF  levels  with  neurodegenerative  and  neuropsychiatric  disorders.  However, 
BDNF is not able to cross the blood-brain barrier and, thus, its delivery to the nervous system 
is a challenge. Therefore, functional diets with the ability to induce production of BDNF in 
the brain may offer an alternative route. The objective of this study was three-fold: first, to 
find out diets that are causally linked to the agonistic activity of BDNF in the neurotrophin 
signaling pathway; second and mainly, to investigate mode-of-action of these functional diets 
through  systems-based  mechanistic  modeling  in  the  context  of  Alzheimer’s  disease;  and 
third, to demonstrate the proof-of-concept application of systems biology methods, that are 
well established in the pharmaceutical sector, to the emerging field of functional food.  
 
Methods: In the first step, two cause-and-effect models of BDNF signaling in two states, i.e. 
normal state and Alzheimer’s disease state, were constructed using published knowledge in 
scientific literature and pathway databases. A “differential model analysis” between the two 
states  was  performed  by  which  mechanistic  mode-of-action  of  BDNF  in  neurotrophin 
signaling pathway could be explained with a high molecular resolution in both normal and 
disease states. The BDNF mode-of-action model was further validated using the “biomarker-
guided validation” approach. In the second step, scientific evidence on the effect of various 
functional diets on BDNF levels and BDNF-related biological processes or outcomes was 
harvested  from  biomedical  literature  using  a  disease-specific  semantic  search.  This 
information was then added to the mechanistic model of BDNF mode-of-action and used to 
substantiate the mode-of-action model.       
 
Results: The differential model analysis resulted in a mechanistic mode-of-action model for Functional Foods in Health and Disease 2014; 4(8):362-369                                                     Page 363 of 369 
the effector BDNF signaling pathway through NTRK receptors (Neurotrophic tyrosine kinase 
receptor type 2) in neurons. The model revealed an amyloid-mediated neurotrophin switch 
mechanism  by  which  the  amyloid-beta  protein  competitively  blocks  BDNF-NTRK2 
downstream signaling under Alzheimer’s conditions, thereby “switching” the entire pathway 
from  its  normal  state  with  neuroprotective  effect  to  the  disease  state  with  a  strong  push 
towards neuron apoptosis. This hypothetical switch mechanism was validated by expressed 
biomarkers as well as empirical data obtained from experimentation of BDNF mimetics in 
animal models. Several functional diets were found in the literature that showed agonistic 
effects on the effector BDNF pathway. These effects are exerted through increased levels of 
BDNF  and  subsequently,  activating  the  BDNF  survival  pathway,  which  leads  to  similar 
observations that have been made with BDNF mimetics in animal models.  
 
Conclusions:  To  our  knowledge,  this  is  the  first  study  to  investigate  mode-of-action  of 
functional  foods  using  systems-based  modeling  approaches.  Moreover,  such  models  can 
answer the question how functional diets can possibly act at the molecular level and interfere 
with the disease mechanism. Using scientific evidence supporting such models, there is a 
possibility to introduce new functional formulations by combining functional ingredients of 
these diets.  
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BACKGROUND 
Alzheimer’s disease (AD) is a neurodegenerative disorder that leads to cognitive dysfunction 
due  to  the  loss  of  neurons  in  the  human  brain.  This  debilitating  disease  imposes  high 
economic, social and emotional burden, and presently there is no definitive diagnostic or 
therapeutic solutions for AD.  
Neurotrophins  and their receptors are among therapeutic candidates  that  have shown 
promising  results  for  the  treatment  of  neurological  diseases.  The  neurotrophins  are  an 
important family of growth factors that initiate a series of molecular signals on the surface of 
neurons  and  induce  the  survival,  development,  and  function  of  neurons  through 
“neurotrophin signaling pathway” [1]. BDNF is the most widely expressed member of the 
neurotrophin family in the human brain, which binds to NTRK2 receptors and activates the 
neurotrophin  signaling.  There  is  accumulated  evidence  that  BDNF  exerts  broad 
neuroprotective effects in animal models of Alzheimer’s disease [2]. For example, BDNF 
infusion in rat and mouse has shown to reverse cognitive decline and restore memory [3]. 
However,  neurotrophin  proteins  cannot  be  directly  applied  as  therapeutic  agents  for 
treatment. They suffer from poor stability in serum, negligible oral bioavailability, and the 
pleiotropic  effects;  most  importantly,  neurotrophins  are  not  able  to  cross  the  blood-brain 
barrier and penetrate the brain [4]. Therefore, to take advantage of therapeutic potential of 
neurotrophins, there is a need for alternative strategies.    
Historically, the concept of “food as medicine” was first suggested by medieval Persian 
practitioners such as Avicenna and Rhazes who developed scientific guidelines on the use of 
natural products for treatment of diseases and health problems [5]. Functional diets enriched 
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synthetic compounds. New nutrition-based strategies should be established to intervene with 
the disease mechanism so that the course of disease progression is reverted to the normal 
condition.  
Unfortunately, for the majority of food ingredients, the mechanistic mode-of-action is 
not known. This requires a sound understanding of disease mechanism at the molecular level 
and the way functional ingredients intervene with this mechanism. Systems-based integrative 
approaches provide a means for meeting this requirement by modeling mechanistic relations 
between disease pathways and health outcomes. In the present paper, we demonstrate the 
application  of  such  a  systems-based  approach  and  explain  the  mode-of-action  of  several 
functional diets in neurotrophin pathway.  
A growing body of evidence links reduced levels of neurotrophic factors to increased 
risk of AD and a number of other neurodegenerative diseases. These findings trigger the 
hypothesis that functional agents or ingredients that rescue the affected neurotrophin pathway 
(by  compensating  for  the  reduced  concentrations  of  BDNF)  may  improve  cognition  and 
memory in AD. In the following, we test this hypothesis and provide supporting evidence for 
dietary elements that act with a similar mode-of-action to BDNF. 
 
METHODS 
In the first step, two cause-and-effect models of BDNF signaling in two states, i.e. normal 
state and Alzheimer’s disease state, were constructed using published knowledge in scientific 
literature and pathway databases. The normal BDNF pathway was reconstructed from the 
neurotrophin pathway in the KEGG database [6]. A part of this pathway model demonstrates 
downstream  signaling  by  BDNF-NTRK2  interaction  through  a  variety  of  intracellular 
signaling  cascades,  transmitting  positive  signals  like  enhanced  survival  and  growth  of 
neurons. This map can be accessed at www.genome.jp/kegg-bin/show_pathway?map04722.     
The perturbed BDNF signaling pathway under AD conditions was built by keyword search of 
the  PubMed  abstracts  (Alzheimer’s  disease  AND  BDNF  AND  neurotrophin  signaling 
pathway; accessed 16.07.2014). Twenty nine retrieved abstracts were manually filtered for 
their relevance and information content on impaired BDNF signaling under AD conditions, 
out  of  which  six  publications  were  qualified  (PMIDs:  11438587,  16187222,  9106250, 
21460223, 21647938, 23599427). Finally, cause-and-effect statements were extracted from 
these abstracts and used to draw the model. Thus, all interactions in this model are supported 
by scientific evidence harvested from the literature.  
In the second step, a “differential model analysis” between the two states was performed 
by aligning the two models. The BDNF mode-of-action model was further validated using 
the “biomarker-guided validation” approach. In this approach, we extracted information on 
the  potential  biomarker  activity  (expression)  of  BDNF  and  NTRK2  from  the  literature, 
manually checked them and mapped onto the differential model. 
In the third step, scientific evidence on the effect of various functional diets on BDNF 
levels and BDNF-related biological processes or outcomes was harvested from biomedical 
literature using an advanced semantic search engine, which can be freely accessed under 
www.scaiview.com/scaiview-academia.html. The following query was formulated: (([Human 
Genes/Proteins:“BDNF”]) AND [MeSH Disease:“Alzheimer Disease”]) AND [NDD:“Diet”]. 
Retrieved  documents  were  manually  checked  and  cause-and-effect  information  was 
extracted. This information was then compared to the mechanistic model of BDNF mode-of-
action and used to substantiate the mode-of-action model.       Functional Foods in Health and Disease 2014; 4(8):362-369                                                     Page 365 of 369 
RESULTS 
The differential model analysis (BDNF-normal vs. BDNF-disease) resulted in a mechanistic 
mode-of-action model for the effector BDNF signaling pathway through NTRK2 receptor in 
neurons  (Figure  1).  The  model  revealed  an  amyloid-mediated  neurotrophin  switch 
mechanism  by  which  the  amyloid-beta  protein  competitively  blocks  BDNF-NTRK2 
downstream signaling under Alzheimer’s conditions. Simultaneously, amyloid-beta promotes 
neuronal death via cross-linking NGFR receptor with NTRK1 and suppressing the survival-
promoting PI3K/Akt pathway, thereby “switching” the entire pathway from its normal state 
with neuroprotective effect to the disease state with a strong push towards neuron apoptosis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic illustration of BDNF mode-of-action in normal and disease states. 
BDNF  signaling  in  normal  state  has  been  indicated  in  green,  whereas  perturbed  BDNF 
signaling  in  disease  state  are  shown  in  red.  This  differential  model  uncovers  the  switch 
mechanism by amyloid-beta under AD conditions. 
 
This  hypothetical  switch  mechanism  was  validated  by  expressed  biomarkers  as  well  as 
empirical data obtained from experimentation of BDNF mimetics in animal models. Table 1 
summarizes biomarker evidence for BDNF and NTRK2 receptor. As evident in this table, 
there are several studies that confirm BDNF and its receptor NTRK2 are downregulated in 
the hippocampus and cortex of AD brains. 
 
Table  1.  Biomarker  evidence  for  BDNF  and  its  receptor.  Studies that have measured 
expression levels of BDNF and NTRK2 collectively confirm reduction of BDNF and NTRK2 
protein levels.  
 
Protein  Expression  Brain region  Organism  No. of 
Evidence 
PMIDs 
BDNF  Down-
regulation  
Hippocampus, 
Cortex 
Human, 
Mouse 
7  12654514, 22870188, 
20807770, 
17990049,9387865, 2044
7730, 1742020   
NTRK2  Down-
regulation 
CA1  neurons, 
Glia, 
Forebrain  
Human, 
Mouse 
5  22209410, 20655510, 
8931004, 16539663, 
10502038 
 
  BDNF    Active 
BDNF 
  Active 
BDNF 
NTRK2 
Active 
NTRK2 
UCHL1 
Neural 
development 
Neural 
homeostasis 
Amyloid 
beta 
Active
NGFR 
NGFR 
+ 
NTRK1 
Neural death 
Neuron 
membrane 
Ceramide 
accumulation 
PI3K/Akt 
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The  biomarker  evidence,  however,  can  be  further  substantiated  by  the  results  from 
translational studies in which synthetic agonists of BDNF have been tested and a positive 
effect on the neural survival pathway has been reported. Table 2 lists studies in which BDNF 
agonists were reported to reverse memory impairment in mouse models of AD. 
 
Table 2. Translational evidence supporting BDNF mode-of-action. Six studies report on 
the mode-of-action of BDNF agonists for improved memory and learning. 
Agent  Proof-of-Concept  Reference 
Compound J147  J147  inducing  the  BDNF  protein 
and  its  downstream  molecules 
reversed  cognitive  impairment  in 
aged AD mice. 
Prior, M., Dargusch, R., Ehren, J. L., 
Chiruta, C., & Schubert, D. (2013). 
Alzheimers Res Ther, 5(3), 1-19. 
7,8-
dihydroxyflavone 
 
7,8-DHF  a  small-molecule  TrkB 
agonist,  reverses  memory  deficits 
and  BACE1  elevation  in  a  mouse 
model of Alzheimer's disease. 
Devi, L., & Ohno, M. (2012). 
Neuropsychopharmacology, 37(2), 
434-444. 
Fingolimod  Fingolimod increases brain-derived 
neurotrophic  factor  levels  and 
ameliorates  amyloid  β-induced 
memory impairment. 
Fukumoto, K., Mizoguchi, H., 
Takeuchi, H., Horiuchi, H., 
Kawanokuchi, J., Jin, S., ...& 
Suzumura, A. (2014). Behavioural 
brain research, 268, 88-93. 
Deoxygedunin  Deoxygedunin  imitates  BDNF's 
biological  activities  through 
activating TrkB 
Jang, S. W., Liu, X., Chan, C. B., 
France, S. A., Sayeed, I., Tang, W., ... 
& Ye, K. (2010). PLoS One, 5(7), 
e11528. 
LM22A 
compounds 
Small  molecule  BDNF  mimetics 
activate TrkB signaling and prevent 
neuronal degeneration in rodents 
Massa, S. M., Yang, T., Xie, Y., Shi, 
J., Bilgen, M., Joyce, J. N., ... & 
Longo, F. M. (2010). The Journal of 
clinical investigation, 120(5), 1774. 
 
According to the above results, it can be hypothesized that any functional ingredient with 
BDNF boosting properties may be able to revert the neural apoptosis to the neural survival 
pathway. 
Several functional diets were found in the literature that showed agonistic effects on the 
effector BDNF pathway  (Table 3). These effects are exerted through increased levels of 
BDNF and subsequently, activating the BDNF pro-survival pathway, which leads to similar 
observations that have been made with BDNF mimetics in animal models. As shown in Table 
3, there are diets with both positive (agonistic) and negative (antagonistic) effects on the 
BDNF signaling pathway. 
 
Table 3. List of diets/ingredients reported in the literature to agonize or antagonize the effects 
of BDNF 
 
Diet / Ingredient  Mode-of-Action  Evidence 
(PMID) 
Tryptophan  Increases BDNF levels in the cerebral cortex   10192916 
Caffeine  Preserves basal levels of BDNF 
Increased hippocampal BDNF 
22706686 
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Carbohydrate diet  Reduces hippocampal BDNF  22836186 
2-deoxy-D-glucose  Increased expression of BDNF  21747957 
Cocoa polyphenols  Triggers  neuroprotection  by  activating  BDNF  survival 
pathway 
23554028 
High-methionine diet  Lowers levels of BDNF  21647626 
High dietary 
cholesterol 
Elevated BDNF mRNA expression   21826472 
Alpha-lipoic acid  Increases the expression of BDNF in the hippocampus 
of rats 
24008266 
High-fat diet  Reduces BDNF expression  20176720 
Lutein  Prevents depletion of BDNF  22211688 
Ginsenoside  Increased expression of BDNF  15663889 
 
DISCUSSION 
Due to lack of disease-modifying treatments and failure of recent drugs, the AD research is 
witnessing a focus shift from treatment to targeted prevention at both scientific and political 
levels  [7,  8].  Healthy  nutrition  has  been  suggested  as  a  preventive  strategy  in  the  risk 
reduction  and  management  of  AD  [9,  10].  Epidemiological  studies  on  relations  between 
dietary factors and cognitive decline have shown that some nutritional ingredients such as 
saturated fatty acids can exacerbate cognitive decline, whereas other ingredients, including 
vitamins and unsaturated fatty acids, are associated with a reduced risk of dementia [11-13]. 
The challenge is, however, to associate epidemiological observations to underlying molecular 
functions  for  such  food  ingredients.  Despite  accumulated  data  and  knowledge  on  the 
preventive effects of nutritional elements and dietary ingredients on AD, their mode-of-action 
is not well understood. We demonstrated that systems modeling of mode-of-action for dietary 
ingredients could support mechanism discovery and substantiation of health outcomes in the 
case of neurotrophin pathway.  
The  neurotrophic  protein  BDNF  and  its  receptor  NTRK2  are  involved  in  neuron 
differentiation and growth. The differential model analysis between the normal and disease 
signaling states in the neurotrophin pathway led to the identification of “chains of causal 
relationships”  that  led  to  completely  new  insights  into  putative  disease  mechanisms, 
supporting  the  amyloid-mediated  neurotrophin  switch  hypothesis  underlying  Alzheimer´s 
disease etiology. In the normal state, UCHL1, a de-ubiquinating enzyme that controls the 
BDNF-mediated retrograde transport, activates BDNF and increases the binding of BDNF to 
its receptor NTRK2, thereby promoting neuronal development and homeostasis. In contrast, 
under  Alzheimer’s  disease  conditions,  amyloid-beta  prevents  the  binding  of  BDNF  to 
NTRK2  receptor,  thereby  blocking  BDNF-NTRK2  downstream  signaling.  This  blockade 
leads to repression of neuron survival, differentiation and growth,  so that abnormal  APP 
processing and amyloid-beta production has been experimentally shown to attenuate BDNF-
NTRK2 signaling [14]. UCHL1 activity is repressed by amyloid-beta, which in turn impairs 
BDNF-NTRK2-mediated  downstream  signaling,  leading  to  diminished  synaptic  plasticity 
and neuronal survival [15]. 
Accordingly, the model was able to link the causal effect of functional diets to the BDNF 
mode-of-action,  spanning  upstream  the  neurotrophin  pathway  all  the  way  to  downstream 
outcomes. This was achieved by an evidence-based approach to explain mode-of-action of 
those dietary elements that intervene mechanistically at the molecular level with the disease 
pathway.  Functional Foods in Health and Disease 2014; 4(8):362-369                                                     Page 368 of 369 
Using such supportive scientific evidence, there is a possibility to introduce new functional 
formulations by combining functional ingredients of these diets. These formulations can then 
be used for development of functional diets that decrease the risk of AD by enhancing the 
neuroprotective factors responsible for the delayed onset of the disease. We believe that this 
approach opens up new opportunities for development of innovative functional products on 
the basis of sound scientific substantiation.   
 
CONCLUSIONS 
Development of innovative novel functional products requires a profound understanding of 
the complex relationships between the ingredient in question and its causal effect on the 
biological processes in the human body. Gaining insight into such a complex system is not 
feasible without consolidating the existing published knowledge and analytical data.  It is 
anticipated  that  systems  modeling  strategies  play  an  increasingly  important  role  in 
development  of  functional  food  products  by  explaining  molecular  mode-of-action  and 
substantiating expected health outcomes.  
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